AXS-07 (meloxicam-rizatriptan)
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Migraine
Conditions
Migraine
Trial Timeline
Aug 31, 2022 → Nov 27, 2024
NCT ID
NCT05550207About AXS-07 (meloxicam-rizatriptan)
AXS-07 (meloxicam-rizatriptan) is a phase 3 stage product being developed by Axsome Therapeutics for Migraine. The current trial status is completed. This product is registered under clinical trial identifier NCT05550207. Target conditions include Migraine.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05550207 | Phase 3 | Completed |
Competing Products
20 competing products in Migraine
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ABP-450 | AEON Biopharma | Phase 2 | 44 |
| Lasmiditan + Placebo | Eli Lilly | Phase 3 | 77 |
| Placebo + LY2300559 | Eli Lilly | Phase 2 | 52 |
| lasmiditan 200 mg + Sumatriptan + matching placebo | Eli Lilly | Phase 1 | 33 |
| ABP-450 + Placebo | AEON Biopharma | Phase 2 | 44 |
| Lasmiditan + Placebo | Eli Lilly | Phase 2 | 52 |
| Ketorolac + Prochlorperazine + Diphenhydramine | Assertio Holdings | Phase 2 | 44 |
| Galcanezumab + Erenumab | Eli Lilly | Approved | 85 |
| Aricept (donepezil hydrochloride) | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 2 | 52 |
| Galcanezumab + Rimegepant + Placebo + Placebo | Eli Lilly | Approved | 85 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Lasmiditan + Placebo | Eli Lilly | Phase 2 | 52 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Lasmiditan | Eli Lilly | Phase 3 | 77 |
| Galcanezumab Prefilled Syringe + Placebo | Eli Lilly | Phase 2 | 52 |
| Emgality 120 MG in 1 ML Prefilled Syringe | Eli Lilly | Approved | 85 |
| Galcanezumab | Eli Lilly | Pre-clinical | 23 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Galcanezumab + Placebo | Eli Lilly | Phase 2 | 52 |